Efficacy of Vemurafenib in Hairy-Cell Leukemia
To the Editor: The BRAF V600E mutation is present in nearly all cases of hairy-cell leukemia. 1 This finding has led to the introduction of BRAF inhibitors for the treatment of chemotherapy-resistant hairy-cell leukemia, and patients have had a good response to the oral inhibitor vemurafenib. 2-4 Constitutive phosphorylation of both extracellular signal-regulated kinase (ERK) and mitogen-activated protein-ERK kinase (MEK) has been considered to be a direct consequence of BRAF activation, with BRAF inhibition resulting in cell death through suppression of this pathway in hairy-cell leukemia. However, data to support this theory are limited, since most patients present with pancytopenia.
We evaluated a patient with purine analoguerefractory hairy-cell leukemia who had biallelic BRAF V600E mutations and a high leukemic burden during treatment with vemurafenib. Because of the high numbers of circulating hairy-cell leukemia cells, it was possible to study the effects of vemurafenib directly in vivo. Vemurafenib induced complete clinical remission with reduction of the viability of CD103+ hairy-cell leukemia cells during therapy (Fig. 1A) . A pull-down and kinase assay showed inhibition of BRAF in leukemic cells in vivo (Fig. 1B) . However, BRAF inhibition was not associated with any major changes in phosphorylation of either MEK or ERK in vivo, as shown by means of both immunoblot and flow cytometry (Fig. 1C) , despite prolonged exposure to vemurafenib.
Our experiments showed an unanticipated uncoupling between the decrease in BRAF activity (together with increased cell death) and MEK-ERK inhibition in vivo; this was not dependent on the duration of exposure to vemurafenib. We cannot rule out the possibility that BRAF inhibition in vivo eventually resulted in suppression of ERK activation in some anatomical compartment other than the blood before leukemic cell death, but this possibility appears to be unlikely. First, our in vivo data clearly showed inhibition of BRAF without any change in phosphorylated ERK levels in leukemic cells, as shown by means of both immunoblot and flow cytometry, while cells were dying (as shown by the increasing level of propidium iodide staining). Second, the lack of effect of BRAF inhibitors on phosphorylated MEK and ERK was previously reproduced during prolonged incubation in vitro of hairycell leukemia cells obtained from the same patient, whereas the MEK 1 and MEK 2 inhibitor PD325901 successfully blocked ERK phosphorylation and induced significant cell death. 5 An alternative signaling pathway, as yet uncharacterized, may therefore be affected by vemurafenib, either directly or through BRAF inhibition, and it may have a strong impact in hairy-cell leukemia cell survival in vivo. These data have implications for the design of possible combination therapies. This 72-year-old man had had hairy-cell leukemia since he was 50 years of age. After an initial splenectomy at that time, he remained in good health for 14 years. A third relapse 21 years after the initial diagnosis was treated with rituximab and 2-chlorodeoxyadenosine, which induced a complete response. However, a florid relapse occurred in less than a year. A DNA sequence showed a biallelic BRAF V600E mutation, and treatment with vemurafenib at a dose of 240 mg twice daily was initiated in April 2013 (22 years after the initial diagnosis). The only clinically significant toxic effect was alopecia. Panel A shows an initial increase followed by a rapid decrease in the patient's peripheral white-cell count and viability of CD103+ cells after administration of vemurafenib. Hematologic recovery began after 2 months of treatment (the complete blood count was monitored daily in samples obtained from the patient before the first daily dose of vemurafenib). Panel B shows a decrease in BRAF kinase activity after treatment with vemurafenib in a kinase cascade assay. BRAF activity was reduced by 75% 1 day after treatment and reduced by 90% by day 8. The T bars indicate standard deviations. In Panel C, a Western blot study (top) showed no changes in the levels of either phosphorylated MEK or ERK after treatment with vemurafenib. Flow cytometry (bottom) showed that ERK1 and ERK2 phosphorylation was also not reduced in CD103+ cells. Letters that do not adhere to these instructions will not be considered. We will notify you when we have made a decision about possible publication. Letters regarding a recent Journal article may be shared with the authors of that article. We are unable to provide prepublication proofs. Submission of a letter constitutes permission for the Massachusetts Medical Society, its licensees, and its assignees to use it in the Journal's various print and electronic publications and in collections, revisions, and any other form or medium.
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